Evolent Health, Inc. (NYSE:EVH) CEO Seth Blackley Acquires 55,225 Shares

Evolent Health, Inc. (NYSE:EVH) CEO Seth Blackley purchased 55,225 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average price of $9.01 per share, for a total transaction of $497,577.25. Following the completion of the acquisition, the chief executive officer now directly owns 762,217 shares of the company’s stock, valued at $6,867,575.17. This trade represents a 7.81 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Evolent Health Trading Up 0.6 %

Shares of Evolent Health stock traded up $0.05 during trading on Monday, reaching $9.04. 643,570 shares of the stock were exchanged, compared to its average volume of 2,054,103. Evolent Health, Inc. has a 1 year low of $8.35 and a 1 year high of $34.51. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock’s fifty day moving average is $10.37 and its 200 day moving average is $17.61. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -11.14 and a beta of 1.49.

Evolent Health (NYSE:EVH) last released its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.35). The business had revenue of $646.54 million for the quarter, compared to analysts’ expectations of $650.92 million. Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. As a group, equities research analysts expect that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Institutional Trading of Evolent Health

Institutional investors have recently added to or reduced their stakes in the business. Covestor Ltd boosted its holdings in shares of Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after acquiring an additional 826 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new position in Evolent Health in the 4th quarter worth approximately $26,000. R Squared Ltd bought a new position in shares of Evolent Health during the 4th quarter valued at about $31,000. AlphaQuest LLC boosted its position in shares of Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock valued at $34,000 after acquiring an additional 3,031 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its position in shares of Evolent Health by 90.7% during the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock valued at $56,000 after buying an additional 2,358 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Canaccord Genuity Group reduced their target price on shares of Evolent Health from $23.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. JMP Securities reiterated a “market outperform” rating and set a $12.00 price objective on shares of Evolent Health in a research note on Friday, February 14th. Piper Sandler restated an “overweight” rating and issued a $16.00 target price (down previously from $17.00) on shares of Evolent Health in a research note on Friday, February 21st. Citigroup reduced their price objective on shares of Evolent Health from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Finally, Oppenheimer lowered their target price on shares of Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, January 24th. One analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Evolent Health has a consensus rating of “Buy” and a consensus price target of $17.79.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.